The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

Vandita Jadeja

Mon, September 21, 2026 at 8:30 PM GMT+3 5 min read

• LLY +0.45%

Quick Read

• LLY posts 48% revenue growth with Mounjaro and Zepbound generating $14.9B in Q2, yet shares are up only 8% year to date.

• Reaching $1,500 by end of 2027 requires just 30% upside and a 39x forward P/E, only modestly above the current base-case multiple.

• FDA approvals for Mounjaro's cardiovascular use and retatrutide's Q1 2027 BLA submission are the stacked catalysts that could drive multiple expansion.

• Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.

Eli Lilly (NYSE:LLY | LLY Price Prediction) is doing something unusual for a mega-cap: growing revenue at 48% year over year while shares trade only 7.8% higher year to date.

Mounjaro and Zepbound combined for $14.9 billion in Q2 revenue, and CEO David Ricks told investors "Lilly's future, after 150 years, has never been brighter." So here is the question I want to answer directly: can LLY shares reach $1,500 by the end of 2027?

Why LLY Shares Are Stuck Despite 48% Revenue Growth

The stock is stalling because expectations reset faster than fundamentals. Shares are down 9.95% over the past month even after climbing 3.34% in the last week.

Investors are digesting a 9% U.S. price decline (excluding rebate adjustments), heavy $2.78 billion in IPR&D charges from four Q2 acquisitions, and a 1-year gain of 52.08% that already priced in a lot of the incretin story. Beta sits at just 0.502, so this is a valuation-digestion story compounded by recent insider selling and Novo Nordisk competition anxiety.

Wall Street Sees 15% Upside. I Think They Are Underselling It

The Street's consensus target is $1,325.39, implying roughly 15% upside from here. Coverage skews bullish: 6 strong buys, 18 buys, 4 holds, 1 sell, and 1 strong sell, with 80% bullish sentiment.

Free Report, Just Released

Why Didn't LLY Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And LLY didn't make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

Our own model base case lands at $1,229.32 (a modest 6.63% upside) with the bull case at $1,383.40 and bear case at $1,051.57, at high confidence (0.9). Both look conservative to me.

With 19 upward EPS revisions for FY2027 in the last 30 days against just 4 downward, the analyst community is quietly repricing this business higher.

Path to $1,500 Per Share

Reaching $1,500 from today's price of $1,152.93 would require a gain of 30.1%. With forward EPS of $38.25, a price of $1,500 implies a forward P/E of 39x. Our base case of $1,229.32 already implies 37x, meaning the bold target requires only 3x of additional multiple expansion.

That is a modest ask given the setup. The compression story is real: consensus FY2027 EPS sits at $47.32, up from $44.49 ninety days ago.

Catalysts are stacking: the August 28, 2026 FDA approval of Mounjaro for cardiovascular risk reduction, the September 18, 2026 approval of Inluriyo for ER+ breast cancer, and Ricks noting "really unprecedented efficacy with this triple acting GLP-1" ahead of the Q1 2027 retatrutide BLA submission.

The primary risk: any FDA setback on the retatrutide pathway could compress the multiple instead of expanding it.

Where LLY Trades Today vs Its Earnings Power

At $1,152.93 against forward EPS of $38.25, LLY currently trades at roughly 30x forward earnings. That is a reasonable multiple for a company growing revenue 47.67% year over year with 54.8% non-GAAP performance margins.

Shares sit near the 52-week high of $1,292.65, well off the 52-week low of $707.59. Ten-year returns of 1,587.78% tell you long-term compounders can absorb premium multiples when EPS growth keeps delivering.

Is $1,500 Realistic? My Verdict

Reaching $1,500 requires a 30.1% gain from here. I think it is realistic, provided three things happen: retatrutide clears the BLA pathway on schedule, Foundayo's 36,000 prescriber base continues expanding, and FY2027 EPS estimates keep drifting toward the $54.94 high end.

What would derail it? A meaningful Novo Nordisk share-grab in obesity or a regulatory delay on retatrutide's biologic classification. Returns at this level shouldn't be expected every year, but we've outlined the blueprint for how Eli Lilly could reach $1,500 in 2027.

Got $1,000? Before You Buy LLY, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And LLY wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact editorial@247wallst.com for any questions or corrections.